Study of Selinexor with Nab-paclitaxel and Adebrelimab as Second-line Treatment for Extensive Stage Small Cell Lung Cancer ES-SCLC

What this Trial Is About

Researchers are exploring new second-line treatments for patients with extensive-stage small cell lung cancer ES-SCLC who relapse within six months after first-line chemotherapy. This trial evaluates the combination of selinexor, adebrelimab, and albumin-paclitaxel to assess its safety and effectiveness. Selinexor works by blocking a protein that helps cancer cells grow, aiming to stop tumor progression and promote cancer cell death. Participants will receive selinexor orally twice a week, adebrelimab intravenously every three weeks, and nab-paclitaxel intravenously on days 1, 8, and 15 of each three-week cycle. This single-arm study uses this combined immunotherapy and chemotherapy regimen as a second-line treatment. The study does not include placebo or comparison groups. During the study, patients will be monitored for progression-free survival over 24 months. Researchers will also measure response rates, disease control, and overall survival within two years. Participants will undergo regular assessments including tumor imaging and health evaluations to track treatment effects and side effects, with follow-up care continuing as needed.

Second-line Immunotherapy for ES-SCLC